35841100|t|Nilotinib modulates LPS-induced cognitive impairment and neuroinflammatory responses by regulating P38/STAT3 signaling.
35841100|a|BACKGROUND: In chronic myelogenous leukemia, reciprocal translocation between chromosome 9 and chromosome 22 generates a chimeric protein, Bcr-Abl, that leads to hyperactivity of tyrosine kinase-linked signaling transduction. The therapeutic agent nilotinib inhibits Bcr-Abl/DDR1 and can cross the blood-brain barrier, but its potential impact on neuroinflammatory responses and cognitive function has not been studied in detail. METHODS: The effects of nilotinib in vitro and in vivo were assessed by a combination of RT-PCR, real-time PCR, western blotting, ELISA, immunostaining, and/or subcellular fractionation. In the in vitro experiments, the effects of 200 ng/mL LPS or PBS on BV2 microglial cells, primary microglia or primary astrocytes pre- or post-treated with 5 microM nilotinib or vehicle were evaluated. The in vivo experiments involved wild-type mice administered a 7-day course of daily injections with 20 mg/kg nilotinib (i.p.) or vehicle before injection with 10 mg/kg LPS (i.p.) or PBS. RESULTS: In BV2 microglial cells, pre- and post-treatment with nilotinib altered LPS-induced proinflammatory/anti-inflammatory cytokine mRNA levels by suppressing AKT/P38/SOD2 signaling. Nilotinib treatment also significantly downregulated LPS-stimulated proinflammatory cytokine levels in primary microglia and primary astrocytes by altering P38/STAT3 signaling. Experiments in wild-type mice showed that nilotinib administration affected LPS-mediated microglial/astroglial activation in a brain region-specific manner in vivo. In addition, nilotinib significantly reduced proinflammatory cytokine IL-1beta, IL-6 and COX-2 levels and P38/STAT3 signaling in the brain in LPS-treated wild-type mice. Importantly, nilotinib treatment rescued LPS-mediated spatial working memory impairment and cortical dendritic spine number in wild-type mice. CONCLUSIONS: Our results indicate that nilotinib can modulate neuroinflammatory responses and cognitive function in LPS-stimulated wild-type mice.
35841100	0	9	Nilotinib	Chemical	MESH:C498826
35841100	20	23	LPS	Chemical	MESH:D008070
35841100	32	52	cognitive impairment	Disease	MESH:D003072
35841100	57	74	neuroinflammatory	Disease	MESH:D000090862
35841100	99	102	P38	Gene	26416
35841100	103	108	STAT3	Gene	20848
35841100	135	163	chronic myelogenous leukemia	Disease	MESH:D015464
35841100	198	210	chromosome 9	Chromosome	9
35841100	215	228	chromosome 22	Chromosome	22
35841100	368	377	nilotinib	Chemical	MESH:C498826
35841100	395	399	DDR1	Gene	12305
35841100	467	484	neuroinflammatory	Disease	MESH:D000090862
35841100	574	583	nilotinib	Chemical	MESH:C498826
35841100	791	794	LPS	Chemical	MESH:D008070
35841100	798	801	PBS	Chemical	MESH:D007854
35841100	805	808	BV2	CellLine	CVCL:0182
35841100	902	911	nilotinib	Chemical	MESH:C498826
35841100	982	986	mice	Species	10090
35841100	1049	1058	nilotinib	Chemical	MESH:C498826
35841100	1108	1111	LPS	Chemical	MESH:D008070
35841100	1122	1125	PBS	Chemical	MESH:D007854
35841100	1139	1142	BV2	CellLine	CVCL:0182
35841100	1190	1199	nilotinib	Chemical	MESH:C498826
35841100	1208	1211	LPS	Chemical	MESH:D008070
35841100	1220	1235	proinflammatory	Disease	
35841100	1241	1253	inflammatory	Disease	MESH:D007249
35841100	1290	1293	AKT	Gene	11651
35841100	1294	1297	P38	Gene	26416
35841100	1298	1302	SOD2	Gene	20656
35841100	1314	1323	Nilotinib	Chemical	MESH:C498826
35841100	1367	1370	LPS	Chemical	MESH:D008070
35841100	1382	1397	proinflammatory	Disease	
35841100	1470	1473	P38	Gene	26416
35841100	1474	1479	STAT3	Gene	20848
35841100	1516	1520	mice	Species	10090
35841100	1533	1542	nilotinib	Chemical	MESH:C498826
35841100	1567	1570	LPS	Chemical	MESH:D008070
35841100	1669	1678	nilotinib	Chemical	MESH:C498826
35841100	1701	1716	proinflammatory	Disease	
35841100	1726	1734	IL-1beta	Gene	16176
35841100	1736	1740	IL-6	Gene	16193
35841100	1745	1750	COX-2	Gene	17709
35841100	1762	1765	P38	Gene	26416
35841100	1766	1771	STAT3	Gene	20848
35841100	1798	1801	LPS	Chemical	MESH:D008070
35841100	1820	1824	mice	Species	10090
35841100	1839	1848	nilotinib	Chemical	MESH:C498826
35841100	1867	1870	LPS	Chemical	MESH:D008070
35841100	1896	1913	memory impairment	Disease	MESH:D008569
35841100	1963	1967	mice	Species	10090
35841100	2008	2017	nilotinib	Chemical	MESH:C498826
35841100	2031	2048	neuroinflammatory	Disease	MESH:D000090862
35841100	2085	2088	LPS	Chemical	MESH:D008070
35841100	2110	2114	mice	Species	10090
35841100	Association	MESH:C498826	MESH:D000090862
35841100	Association	MESH:D008070	11651
35841100	Negative_Correlation	MESH:C498826	MESH:D008569
35841100	Negative_Correlation	MESH:C498826	16176
35841100	Positive_Correlation	MESH:D008070	MESH:D008569
35841100	Negative_Correlation	MESH:C498826	11651
35841100	Negative_Correlation	MESH:C498826	12305
35841100	Association	MESH:C498826	MESH:D003072
35841100	Association	MESH:C498826	MESH:D007249
35841100	Negative_Correlation	MESH:C498826	20656
35841100	Association	MESH:D008070	26416
35841100	Association	MESH:D008070	MESH:D007249
35841100	Association	MESH:D008070	20848
35841100	Association	MESH:C498826	26416
35841100	Negative_Correlation	MESH:C498826	17709
35841100	Association	MESH:C498826	20848
35841100	Association	MESH:C498826	MESH:D008070
35841100	Association	MESH:D000090862	26416
35841100	Association	MESH:D000090862	20848
35841100	Positive_Correlation	MESH:D008070	MESH:D003072
35841100	Negative_Correlation	MESH:C498826	16193
35841100	Association	MESH:D008070	20656

